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Innovative	  Influenza	  vaccines,	  a	  
challenging	  regulatory	  path	  in	  pandemic	  
situations
Amine	  Kamen,	  Prof.
Canada	  Research	  	  Chair	  in	  Bioprocessing	  of	  Viral	  Vaccines
Researcher	  Emeritus	  National	  Research	  Council	  of	  Canada	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Influenza
• Influenza	  viruses	  :
ü Annual	  epidemics	  
ü high	  probability	  of	  new	  	  influenza	  pandemics
• Up  to  500,000  deaths  due  to  influenza   infection  
occur  annually,  with  3-­5  million  cases  of  severe  
illness
• Pandemic	  Influenza	  preparedness	  plan	  requires	  rapid	  
responses	  and	  capacity	  for	  vaccine	  manufacturing
• Approximately	  70%	  to	  90%	  in	  healthy	  adults	  <65	  years	  
of	  age	  when	  the	  vaccine	  and	  circulating	  viruses	  are	  
well-­‐matched	  (CDC)	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conserved  region  of  HA  &  NA?17  Hemagglutinin 
X 
9  neuraminidase
153 different virus 
subtypes,
over 11900 different 
strains (A, human 






• Attach	  to	  cell	  via	  binding	  
HA1	  to	  sialic	  acid	  
receptors
• HA,	  NA,	  M2	  produced	  
and	  sent	  to	  cell	  
membrane
• M1	  joins	  via	  binding	  to	  
HA	  NA	  or	  M2
• Released	  from	  cell	  via	  
budding,	  NA	  cleaves	  
sialic	  acid	  which	  HA1	  
could	  bind	  back	  to
Neumann,  G.,  Noda,  T.,  &  Kawaoka,  Y.  (2009).  Emergence  and  pandemic  potential  of  
swine-­origin  H1N1  influenza  virus.  Nature,  459(7249),  931–9.
Current Influenza  Vaccine  Manufacturing
Important  to  complement  with  new  flu  
vaccine  production  method
more  rapid,  more  











trivalent:  2  influenza  A  &  1  
influenza  B  virus  strains  
currently:  H1N1  &  H3N2  or  




















12  – 16  
weeks
16  – 20  
weeks
Increase of  vaccine Supply
Current production capacity
Slide  adapted  from  US  department  of  Health  Services    Influenza  vaccine  action  plan
Opportunity:	  “More	  and	  better	  influenza	  
vaccine,	  sooner”
62016-­‐07-­‐01
• FDA  approved  Flucelvax,  the  first  seasonal   influenza  vaccine  
manufactured  using  cell  culture  technology  Nov.  20,  2012
http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm328982.htm
• FDA  approved  FluBlok,  the  first  trivalent  influenza  vaccine  
made  using  an  insect  virus  (baculovirus)  expression  system  
and  recombinant  DNA  technology.  Jan  16,  2013  
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm335891.ht
m




HA  =  active  ingredient  
in  licensed  vaccine
Improving	  Production	  of	  an	  influenza	  
vaccine
Human  Influenza
Meghrous  et  al.  (2010)  Vaccine
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Influenza	  vaccine manufacturing:	  other	  
technologies	  
•Insect  cell  VLPs:  Novavax
•Mammalian  cell  VLPs  (poster  #  10)    
•Plant  VLPs:  Medicago
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Colle c tion o f spe cimens a nd d isease /ep idemiolog ical data
Dia gnos is , viru s iso la tion in MDCK, p re liminary analys is
Tho rough a n tigen ic a nd genetic analys is
Fe rre t a n tise ra p roduction
Re vie w a nd selec tion of cand ida te viru se s for va ccine use
An tige n ic a nd
7a ge ne tic
characterization of 
reassortants
Availabilit y of vaccine virus es and s tandardized reagents
Viru s iso la tion in e ggs
1-3 we e ks
Se ro log ic a l s tud ies
Se a s o n a l H5N1
De ve lopme nt o f
s ta nda rd ize d reagen ts
fo r
ina c tiva te d va ccines
Evaluation of growth 
property
Cla ss ic a l
re a sso rtme n t o f h igh - g rowth
viru se s fo r H1N1 &H3N2
Reassortment of high- growth viruses 
using reverse genetics (and full safety 
testing)
Process of influenza vaccine virus selection and development
De ve lopme nt o f
s ta nda rd ize d reagen ts
fo r
ina c tiva te d va ccines
An tige n ic a nd

















a ll ye a r ro u n d
h o u rs -3 we e ks
1-3 we e ks
1-3 we e ks
6 we e ks
4 we e ks6 we e ks
1 we e k
3 we e ks
3-16 we e ks
3-4 we e ks
4 we e ks 6 we e ks
1 we e k
WHO,  
Erich  Hoffmann,    Scott  Krauss,    Daniel  Perez,    Richard  Webby,    Robert  G  Webster,  Eight-­plasmid  system  for  rapid  generation  of  
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Single-­‐Radial Immunodiffusion assay (SRID) -­‐ Antigen concentration is determined by the degree
of antigen/antibody precipitate around a well into which detergent solubilized virus is placed.
A standardized antigenpreparation and a specific polyclonal antibody are required.
• An agarose solution containing a predetermined amount of polyclonal antibody is plated in
a thin gel layer which is punched with 3 to 4mm holes.
• Dilutions of standard antigen are placed into the wells alongside samples with unknown antigen
concentrations. The gel is incubated and resulting precipitin rings are visiualized with Coomassie
blue stain.






Alternative	  methods	  to	  SRID
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Poster  #  8  by  Manceur  A.  et  al
WHO,	  Influenza	  Vaccine	  Response	  during	  the	  Start	  
of	  a	  Pandemic	  – WHO	  Informal	  Consultation	  REPORT	  2015	  
• Vaccine	  manufacturers	  should	  ensure	  that	  they	  have	  import	  
permits	  in	  place	  for	  receipt	  of	  CVVs.	  This	  should	  include	  wild-­‐
type	  viruses,	  conventional	  reassortants	  and	  reassortants	  
generated	  by	  RG,	  which	  in	  some	  countries	  are	  judged	  to	  be	  
genetically	  modified	  organisms	  (GMOs).	  
• It	  is	  clear	  that	  the	  availability	  of	  pandemic	  vaccine	  reagents	  
may	  be	  problematic.	  In	  2009,	  alternative	  potency	  assays	  were	  
used	  during	  the	  early	  stages	  of	  pandemic	  vaccine	  production.	  
This	  is	  an	  area	  for	  considerable	  research	  and	  WHO	  has	  




• Coordination	  between	  WHO-­‐CC,	  ERL,	  and	  
National	  Authorities
• 1)	  Cell	  culture	  production	  still	  depends	  on	  viral	  
seed	  stocks	  (CVV)	  made	  in	  eggs
– Reverse	  genetics	  in	  cell	  culture	  to	  meet	  pandemic	  	  
timelines	  
• 2)	  SRID:	  delays	  in	  generation	  of	  specific	  
antibodies
– Alternative	  potency	  assay	  (adapted	  to	  the	  new	  
influenza	  antigen	  design)
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““Science  will  fulfill  its  promises  when  
the  benefits  are  equally  shared  by  the  
REALLY  poor  of  the  world”  
-­ César    Milstein  –
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